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Introduction
Predominantly neutrophilic inflammatory infiltrates are
seen in a subset of chronic urticaria patients, with lesions
that tend to be less itchy and poorly responsive to antihis-
tamine therapy.[1,2] There have been reports of patients
with neutrophilic dermatoses presenting with extracuta-
neous inflammation.[3] We present two patients with
neutrophilic urticaria and extracutaneous symptoms likely
mediated by interleukin 1 (IL-1) and not associated with a
known connective tissue disease. We propose the term
“neutrophilic urticaria with systemic inflammation”
(NUSI) to describe a spectrum of diseases, which includes
neutrophilic urticaria, and highlights the role of IL-1 in
driving this particular inflammatory process.
Case report
Patient 1: A 47-year old female presented with urticaria
and associated night sweats, fevers and polyarticular arthri-
tis. Acute phase reactants were elevated with worsening of
symptoms. Initial treatment with topical and systemic
corticosteroids, antihistamines, and immunosuppressants
was unsuccessful. 100% clinical resolution was achieved
with anakinra, an Il-1 receptor antagonist. Patient 2: A
26-year old female presented with urticaria and associated
joint pain and swelling. Initial treatment included antihis-
tamines, colchicine, and dapsone. Only colchicine provided
moderate benefit, but was stopped due to significant
GI-discomfort. Anakinra was initiated; the patient now has
100% control on daily therapy.
Discussion
The cases described in this report represent a multi-
systemic inflammatory entity: neutrophilic urticaria with
systemic inflammation (NUSI). In NUSI, there is abrupt
onset of neutrophilic urticaria occurring in tandem with
inflammatory arthritis and other systemic symptoms, and
complete control of symptoms is achieved with IL-1
blockade. NUSI likely lies on a spectrum with clinically
similar autoinflammatory diseases, with IL-1 dysregulation
and subsequent neutrophil-driven inflammation leading to
cutaneous symptoms progressing from varied severity of
neutrophilic urticaria to include Sweet’s syndrome to
possibly pyoderma gangrenosum. The diagnosis of NUSI
is an important one to consider in patients who present
with antihistamine-resistant urticaria in combination with
systemic inflammatory symptoms, with IL-1 blockade a
viable option for therapy.
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